AcelRx Pharma (ACRX) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 7:30 AM EDTRealigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million
Completed acquisition of Lowell Therapeutics and nafamostat franchise, including Niyad with Breakthrough Device Designation
 Continued DSUVIA sales momentum with fourth consecutive quarter of sales volume growth, including 64% commercial (ex-DoD) growth in Q1 2022 compared to Q4 2021
$39.3 million of cash and short-term investments at March 31, 2022
Webcast and Conference Call to be held today at 8:30 am... More
